RT Journal Article
SR Electronic
T1 Employing a Systematic Approach to Biobanking and Analyzing Clinical and Genetic Data for Advancing COVID-19 Research
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.24.20161307
DO 10.1101/2020.07.24.20161307
A1 Daga, Sergio
A1 Fallerini, Chiara
A1 Baldassarri, Margherita
A1 Fava, Francesca
A1 Valentino, Floriana
A1 Doddato, Gabriella
A1 Benetti, Elisa
A1 Furini, Simone
A1 Giliberti, Annarita
A1 Tita, Rossella
A1 Amitrano, Sara
A1 Bruttini, Mirella
A1 Meloni, Ilaria
A1 Pinto, Anna Maria
A1 Raimondi, Francesco
A1 Stella, Alessandra
A1 Biscarini, Filippo
A1 Picchiotti, Nicola
A1 Gori, Marco
A1 Pinoli, Pietro
A1 Ceri, Stefano
A1 Sanarico, Maurizio
A1 Crawley, Francis P.
A1 GEN-COVID Multicenter Study
A1 Renieri, Alessandra
A1 Mari, Francesca
A1 Frullanti, Elisa
YR 2020
UL http://medrxiv.org/content/early/2020/08/14/2020.07.24.20161307.abstract
AB Within the GEN-COVID Multicenter Study, biospecimens from more than 1,000 SARS-CoV-2-positive individuals have thus far been collected in the GEN-COVID Biobank (GCB). Sample types include whole blood, plasma, serum, leukocytes, and DNA. The GCB links samples to detailed clinical data available in the GEN-COVID Patient Registry (GCPR). It includes hospitalized patients (74.25%), broken down into intubated, treated by CPAP-biPAP, treated with O2 supplementation, and without respiratory support (9.5%, 18.4%, 31.55% and 14.8, respectively); and non-hospitalized subjects (25.75%), either pauci- or asymptomatic. More than 150 clinical patient-level data fields have been collected and binarized for further statistics according to the organs/systems primarily affected by COVID-19: heart, liver, pancreas, kidney, chemosensors, innate or adaptive immunity, and clotting system. Hierarchical Clustering analysis identified five main clinical categories: i) severe multisystemic failure with either thromboembolic or pancreatic variant; ii) cytokine storm type, either severe with liver involvement or moderate; iii) moderate heart type, either with or without liver damage; iv) moderate multisystemic involvement, either with or without liver damage; v) mild, either with or without hyposmia. GCB and GCPR are further linked to the GEN-COVID Genetic Data Repository (GCGDR), which includes data from Whole Exome Sequencing and high-density SNP genotyping. The data are available for sharing through the Network for Italian Genomes, found within the COVID-19 dedicated section. The study objective is to systematize this comprehensive data collection and begin identifying multi-organ involvement in COVID-19, defining genetic parameters for infection susceptibility within the population and mapping genetically COVID-19 severity and clinical complexity among patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The GEN-COVID study was approved by the University Hospital of Siena Ethical Review Board (Protocol n. 16929, dated March 16, 2020). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and samples referenced here in the GEN-COVID Patient Registry and the GEN-COVID Biobank are available for consultation. You may contact the corresponding author, prof. Alessandra Renieri (e-mail: alessandra.renieri{at}unisi.it) for further information. http://nigdb.cineca.it/index.php http://www.nig.cineca.it/